Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)

Compare
6.87
-0.02
(-0.29%)
At close: April 11 at 3:04:45 PM GMT+8
Loading Chart for 002252.SZ
  • Previous Close 6.89
  • Open 6.89
  • Bid 6.87 x --
  • Ask 6.88 x --
  • Day's Range 6.83 - 6.93
  • 52 Week Range 6.42 - 8.68
  • Volume 40,512,115
  • Avg. Volume 41,616,488
  • Market Cap (intraday) 45.603B
  • Beta (5Y Monthly) 0.54
  • PE Ratio (TTM) 24.54
  • EPS (TTM) 0.28
  • Earnings Date --
  • Forward Dividend & Yield 0.07 (0.98%)
  • Ex-Dividend Date Sep 30, 2024
  • 1y Target Est 6.40

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

www.raas-corp.com

3,254

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002252.SZ

View More

Performance Overview: 002252.SZ

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002252.SZ
4.85%
SSE Composite Index (000001.SS)
3.39%

1-Year Return

002252.SZ
1.82%
SSE Composite Index (000001.SS)
6.72%

3-Year Return

002252.SZ
23.39%
SSE Composite Index (000001.SS)
2.24%

5-Year Return

002252.SZ
11.62%
SSE Composite Index (000001.SS)
15.79%

Compare To: 002252.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002252.SZ

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    45.60B

  • Enterprise Value

    41.89B

  • Trailing P/E

    24.45

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.37

  • Price/Book (mrq)

    1.46

  • Enterprise Value/Revenue

    5.02

  • Enterprise Value/EBITDA

    18.53

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.93%

  • Return on Assets (ttm)

    4.32%

  • Return on Equity (ttm)

    6.00%

  • Revenue (ttm)

    8.34B

  • Net Income Avi to Common (ttm)

    1.83B

  • Diluted EPS (ttm)

    0.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.71B

  • Total Debt/Equity (mrq)

    0.00%

  • Levered Free Cash Flow (ttm)

    102.24M

Research Analysis: 002252.SZ

View More

Company Insights: 002252.SZ

Research Reports: 002252.SZ

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.